Study to Compare the Level of Elafibranor in Blood after Repeat Administration in Japanese and non-Asian Healthy Participants
This study is intended to measure the blood levels of Elafibranor and one of its metabolites in Japanese and non-Asian Healthy Participants, to be able to compare how the body absorbs, distributes, and eliminates Elafibranor after Repeat Administration, in order to support inclusion of Japanese patients in the planned clinical studies with elafibranor.
Study to Compare the Level of Elafibranor in Blood after Repeat Administration in Japanese and non-Asian Healthy Participants
- 09 January 2025 - 1 mins read
This study is intended to measure the blood levels of Elafibranor and one of its metabolites in Japanese and non-Asian Healthy Participants, to be able to compare how the body absorbs, distributes, and eliminates Elafibranor after Repeat Administration, in order to support inclusion of Japanese patients in the planned clinical studies with elafibranor.
Related Clinical Trials
09 January 2025
1 mins read
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
09 January 2025
1 mins read
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
09 January 2025
1 mins read
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
09 January 2025
1 mins read
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
09 January 2025
1 mins read
Dysport® Adult Lower Limb Spasticity Follow-on Study
09 January 2025
1 mins read
Dysport® Pediatric Lower Limb Spasticity Study
09 January 2025
1 mins read
Dysport® Adult Lower Limb Spasticity Study
09 January 2025
1 mins read
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
09 January 2025
1 mins read
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
09 January 2025
1 mins read